Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant and Palonosetron for ADC-induced Nausea and Vomiting
NCT07692451Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2026
- Primary completion
- Jul 2027
01
Overview
Phase 2, randomised, double-blind trial of fosrolapitant in Nausea and Vomiting (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Complete Response Rate at 14 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
fosrolapitant
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT07692451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692451.